CLINICA 100 TOP 10: Danaher
This article was originally published in Clinica
Executive Summary
Edging its way into the Top 10 for the first time is Danaher. The company moved up one position to No 10 in our Clinica 100 league table*. It continues to be No 2 in the IVD list, behind Roche. Danaher was involved in one of 2015’s mega-mergers, making its biggest buy ever with a $13.8bn deal for filtration technology specialist Pall. The companies serve not only the life sciences market (Danaher more so than Pall) but also other non-healthcare related industries (Pall more so than Danaher). With the acquisition of Pall, the bulked up Danaher plans to split into two publicly listed companies – the concern that will retain the Danaher name will encompass Danaher’s life sciences, diagnostics and dental segments and the other concern will consists of the water quality and product identification platforms and most of the acquired Pall businesses.